




Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder accounting for 60% to 80% of all dementia cases. AD neuropathology is characterized by both intracellular tau and extracellular amyloid-β (Aβ), the latter of which is thought to accumulate a decade or more before onset of clinical symptomology. Cognitive hallmarks of disease progression include initial mild cognitive impairment followed by progressive decline in cognition, memory, and routine daily functioning. Epidemiologic studies suggest some premorbid personality traits are a risk factor for incident AD and may begin before clinical onset. Two hypotheses have emerged to explain this association: The Risk Factor hypothesis posits that personality is a true pre-morbid risk factor independent of early disease pathology, while the Reverse Causality hypothesis holds that personality reflects behavior change as an early indicator of sub-clinical AD neuropathology. The aim of this research was to evaluate the Reverse Causality hypothesis by evaluating the cross-sectional relationship between baseline Aβ and personality scores and test whether Aβ levels predict change in personality in cognitively normal older adults. 
Data were collected between 2010 and 2017 from two University of Pittsburgh imaging studies. All individuals completed a baseline 11C Pittsburgh Compound B (PiB)-PET scan measuring brain Aβ deposition and NEOTM-FFI-3 personality assessment (N=106). Among individuals with at least one APOE allele variant, PiB(+) status was significantly associated with higher neuroticism score F(3,17)= 4.918, p=.040, and lower conscientiousness score, F(3,17)=13.665, p= .002. In the longitudinal model, only openness (β =-0.271, p=0.010) and conscientiousness (β = -0.225, p=0.031) were associated with baseline age and there was no association between length of follow-up and personality change. The data suggest that there is no longitudinal association between baseline PiB status and self-reported personality change in non-demented older adults. Results are inconsistent with the Reverse Causality hypothesis indicating that personality change may not be a sufficient indicator of subclinical AD neuropathology. This research has important public health significance as it adds to better understanding of brain Aβ and personality changes in older adults at risk of developing AD, which may eventually lead to new early interventions. 
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It has become clear in recent decades that global population growth has reached unprecedented levels. This phenomenon is primarily attributed to increases in overall life expectancy as well as decreases in fertility rates around the world and has resulted in an increase in the absolute number and relative proportion of adults over age 65 (World Health Organization, 2015). In 2016, the National Institute of Health estimated that 8.5% (617 million) of the population worldwide are 65 and older with projections reaching nearly 17% (1.6 billion) by 2050. Older age is highly correlated with the development of chronic conditions. As the global population continues to increase, the incidence and prevalence of individuals with chronic disease will also rise. 
Alzheimer’s Disease (AD) is the leading cause of disability and poor health in the United States and the fifth leading cause of death in individuals over 65 (Alzheimer's Association, 2017a). Hallmarks of disease progression include initial mild cognitive impairment (MCI) followed by progressive decline in cognition, memory, and routine daily functioning. Additionally, AD neuropathology is characterized by both intracellular tau and extracellular amyloid-β (Aβ), the latter of which is thought to accumulate a decade or more before onset of clinical symptomology. At present, all existing medications targeting AD are unable cure or stop the progression of disease but instead aim to reduce and stabilize symptoms for a limited time (Alzheimer's Association, 2018b). Consequently, it has become imperative for healthcare professionals to better understand the etiology and risk factors which contribute to the development of AD. As researchers develop a better understanding of brain aging in both healthy and diseased states, a shift in drug development aiming to modify the disease process itself or prevent development altogether has emerged. One major challenge facing these researchers is the continued difficulty in identifying the earliest prodromal changes that occur in AD. At present, both clinicians and researchers employ a variety of different methods to identify early indicators of cognitive decline including: a medical history review, interviews of close relatives or friends, neurological and neuropsychological tests, assessments of independent function, daily living, and mood, and laboratory tests including neuroimaging or bloodwork (Alzheimer's Association, 2018c). 
One way researchers have attempted to improve detection of subclinical AD and other dementias is by closely observing behavioral and personality change patterns of older adults to better understand the earliest signs of impairment (Balsis, Carpenter, & Storandt, 2005). With greater access to neuroimaging techniques and improved biomarker detection, studies exploring the relationship between behavioral and neuropathological facets of dementia have become increasingly possible. The purpose of this paper is twofold. The first section provides a comprehensive review of cognitive and personality factors as they relate to our current knowledge of AD. The second part includes a description of two analyses which examine the relationship between Amyloid-β and the 5-factor model of personality in nondemented older adults.  
1.1	Aging and Cognition
Healthy aging has been defined as the development and maintenance of optimal physical, mental, social well-being, and function in older adults (Lang et al., 2006). The avoidance of diseases resulting in disability, high cognitive and physical function, and active engagement with life are key factors in the perceived healthy aging process (J. W. Rowe & Kahn, 1997). However, even those who age “well” cannot avoid normal brain changes over time. Age-related brain changes include decreases in total brain volume, loss of both grey and white matter, breakdown of neuronal integrity, decreased cerebral glucose metabolism, and decreased vascular integrity  ADDIN EN.CITE (Fiala, 2007; Fjell Anders & Walhovd Kristine, 2010; Lakatta & Levy, 2003; Marcus, Mena, & Subramaniam, 2014; Šimić, Kostović, Winblad, & Bogdanović, 1997). Additionally, age-related behavioral changes may include intermittent confusion, shifts in mood and personality and occasional poor decision making (Alzheimer's Association, 2018a; Gazzaley, Cooney, Rissman, & D'esposito, 2005). 
1.2	Alzheimer’s Disease
It has been well established that brain changes occur as part of the healthy aging process yet there are qualitative differences in AD indicating distinct pathological processes which deviate from normal aging  ADDIN EN.CITE (Driscoll et al., 2009; Fjell Anders & Walhovd Kristine, 2010; West, Coleman, Flood, & Troncoso, 1994). AD is a progressive neurodegenerative disorder which accounts for 60-80% of all dementia cases. In 2017, A conservative estimate of 5.5 million individuals in the United states were living with AD. By the year 2050, it is estimated that a new person in the United States will develop AD every 33 seconds (Alzheimer's Association, 2017a; World Health Organization, 2015). Two types of AD have been identified: early and late onset. Early onset disease affects individuals under the age of 65, often as early as their 30s or 40s, and accounts for an estimated 5% of AD cases (Mendez, 2012). Early onset familial AD is seen in approximately 3.5% of the population with AD and results from the inheritance of a variety of single gene autosomal dominant mutations on chromosome 21, 14, or 1 from a biological parent (Harvey, Skelton-Robinson, & Rossor, 2003). Although specific genes have not been identified, early onset AD not linked to family history are also believed to have a strong genetic component (National Institute on Aging, 2015). Late onset AD is the most common form of AD and is likely caused by a combination of genetic, lifestyle and environmental factors throughout the life course. 
One of the first clinical indicators of AD development is the presence of mild cognitive impairment (MCI). A diagnosis of MCI results from identification of cognitive decline that does not meet criteria for dementia and does not significantly impair functionality during most daily life activities. An individual diagnosed with MCI has increased risk of developing AD or another dementia. Estimated conversion rates are 33.6% in specialist settings and 28.9% in population-based samples over follow-up ranging from 3 to 10 years  ADDIN EN.CITE (Mitchell & Shiri-Feshki, 2009). 
Symptoms of initial decline in both MCI and AD commonly present as short-term memory dysfunction and dysfunction of cognitive processes including executive function, language, and visuospatial ability (Gauthier et al., 2006; Sacuiu, 2016). Behavioral disease indicators include wandering, sleep disturbances, and changes in mood and personality such as anger and apathy (Alzheimer's Association, 2018a). AD pathology may begin to develop years or even decades before clinical onset and diagnostic criteria has been broadened to better reflect recent development in the field  ADDIN EN.CITE (McKhann et al., 2011; Sperling et al., 2011; World Health Organization, 2017). Although the underlying pathologic process of AD development continues to elude researchers, a variety of risk factors which contribute to the overall risk of disease are being investigated.
1.2.1	Risk Factors
It is currently accepted that the pathogenesis of AD is complex and multifactorial with a variety of non-modifiable and modifiable risk factors. Among all factors, age is the most prominent indicator of AD risk. Both incidence and prevalence are highest in those above 65 years old and risk for AD doubles every 5 years beyond that point. By age 85, there is nearly a 50% chance of developing the disease (Alzheimer's Association, 2017a). 
The major genetic risk factor associated with AD is the ε4 variant of the apolipoprotein E (APOE4) gene located on chromosome 19. Three isoforms of the gene exist (ε2, ε3, ε4) each of which have different effects on the structure and function of the gene  ADDIN EN.CITE (Castellano et al., 2011; Corder et al., 1994). Expression of the ε4 variant increases the risk of developing AD roughly 4 to 12-fold compared to the ε3 variant and decreases the age of onset by 8 years (Mahley & Huang, 2012). Prevalence of APOE4 among AD patients is variable across cultures with the highest estimates in Northern Europe and lowest estimates appearing in Asia and Southern Europe  ADDIN EN.CITE (Ward et al., 2012).  ADDIN EN.CITE Dar-Nimrod et al. (2012) found that the relationship between APOE4 and cognitive function as well as AD may be moderated by high levels of both neuroticism and extraversion.
Subjective cognitive complaints (SCCs) are concerns an individual may have regarding their cognitive abilities regardless of their objective cognitive status. They are common among the elderly and may be attributed to both the natural and pathological aging process (Stenfors, Marklund, Magnusson Hanson, Theorell, & Nilsson, 2014). Examples include but are not limited to the belief that their memory is not as good as it used to be, noting increased instances of forgetfulness, and experiencing greater difficulty with mental tasks that were once easy.  SCCs have been previously identified as potential early indicators for cognitive decline and dementia (Jessen et al., 2010). However, Slavin et al. (2010) found that SCCs are highly prevalent among older adults and correlate strongly with other psychological factors including depression, anxiety, and neuroticism. The authors recommend caution in overinterpreting the presence of SCCs when diagnosing MCI. Additionally, other researchers believe SCCs should not be considered diagnostic criteria for MCI since not everyone with mild impairment has complaints and vice versa  ADDIN EN.CITE (Edmonds, Delano-Wood, Galasko, Salmon, & Bondi, 2014).
Additional risk factors which have been researched include: Family history of AD, female sex, lower education, high blood pressure, obesity, diabetes mellitus, alcohol consumption, depression, head injury, smoking, high cholesterol levels and cerebrovascular markers including white matter hyperintensities and microbleeds  ADDIN EN.CITE (Breteler, Claus, van Duijn, Launer, & Hofman, 1992; Mielke, Vemuri, & Rocca, 2014; Sacuiu, 2016; Zlokovic, 2011). 
1.2.2	Pathophysiology
The pathological process of AD is characterized by the breakdown of neuronal integrity resulting in widespread atrophy of brain tissue in afflicted areas. The primary phenotypic changes in AD include (1) Buildup of amyloid-beta peptide (Aβ) plaques in the brain parenchyma and (2) accumulation of neurofibrillary tangles (NFTs) within neurons. Additional hypotheses including the cholinergic and neurovascular hypotheses have been proposed and discussed elsewhere  ADDIN EN.CITE (Craig, Hong, & McDonald, 2011; Deane & Zlokovic, 2007). 
1.2.2.1	The Amyloid Hypothesis
The amyloid hypothesis posits that an imbalance in Aβ production and clearance is the fundamental cause of AD and subsequent progression  ADDIN EN.CITE (Selkoe & Hardy, 2016). Aβ peptides derive from the amyloid precursor protein, an integral membrane protein found in many tissues as well as neuronal synapses. These peptides form oligomers which are considered stickier than other amyloid variants resulting in formation of plaques. Misfolded oligomers have been observed to cause synaptic dysfunction and play an active role in disrupting additional Aβ oligomers supporting plaque accumulation  ADDIN EN.CITE (Fiala, 2007; Haass & Selkoe, 2007). This hypothesis has gained support over the past 20 years with many genetic studies identifying a relationship between abnormal amyloid precursor protein (APP), Aβ plaque accumulation and AD development particularly among those with early onset familial AD (Tanzi & Bertram, 2005). 
A variety of criticisms of this hypothesis have emerged based on studied in mouse models arguing that Aβ is not as cytotoxic as previously assumed (Kametani & Hasegawa, 2018). In addition, the presence of Aβ alone is not enough to merit a diagnosis of AD or explain cognitive state. Figure 1. illustrates the challenge when using neuroimaging methodologies to visualize Aβ and make conclusions regarding its relationship with AD. In Figure1(b), three separate individuals with similar burden but different clinical states demonstrate that the relationship between Aβ and AD is not as clear-cut as portrayed in Figure1(a). Despite criticisms, the majority of the scientific community continues to support the hypothesis due to a wealth of past and current research linking Aβ to AD. As the role of Aβ in the causal pathway of AD becomes clearer, it will be necessary to revise the hypothesis to reflect each new development. 


Figure 1(a) PiB-PET scan of an PiB(+) AD patient versus a PiB(-) control. (b) PiB (+) Alzheimer’s patient, PiB (+) patient with mild cognitive impairment, and PiB (+) normal control 
Figure 1. Amyloid-β PIB-PET Scans
1.2.2.2	The Tau Hypothesis
Another popular hypothesis in AD development is the Tau hypothesis which posits that abnormal tau proteins initiate the disease cascade. Tau proteins, coded by chromosome 17, primarily stabilize microtubules in cells and are abundant in central nervous system neurons. Aggregates of hyperphosphorylated tau form NFTs which interfere with intracellular transport and function, ultimately leading to cell death  ADDIN EN.CITE (Goedert, Trojanowski, & Lee, 1997; Maccioni, Farias, Morales, & Navarrete, 2010). Tau pathology has been linked to a variety of neurodegenerative disorders with dementing symptomology including but not limited to frontotemporal dementia, Parkinson’s, Pick’s disease and progressive supranuclear palsy (Kametani & Hasegawa, 2018). Similar to Aβ, hyperphosphorylated tau proteins may convert normal tau to abnormal functionality state  ADDIN EN.CITE (Hasegawa, 2016). In a recent imaging study, the presence of NFTs correlated to cognitive performance in the earliest stages of AD  ADDIN EN.CITE (Johnson et al., 2016). The development of novel tau biomarkers suggests promising insights to this hypothesis in the near future.  
1.3	Amyloid-B Neuroimaging Modalities
In the past, a definitive diagnosis of AD could only be made after associated pathology was confirmed post-mortem. Improved biomarker identification and neuroimaging techniques have opened new routes toward understanding the pathologic processes of AD in vivo. It is common that diagnosis of AD is only reported after ruling out other similar diseases. In these cases, the presence of a biomarker in conjunction with a clinical history and neuropsychological tests can provide a clearer and more rapid clinical diagnosis (McKhann et al., 2011). One challenge facing biomarkers is their imprecise nature. It is often possible to identify results as “normal” or “abnormal” but many cases often indicate inconclusive pathology making a definitive diagnosis difficult. In these cases, qualitative interpretations must be made of quantitative values along with the judgement of the clinician. Included below is a brief description of the two dominant AD neuroimaging modalities and their importance in the diagnostic process. 
1.3.1	Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is an imaging technique which uses a superconducting magnet to transmit a radiofrequency into the body. In response to the radiofrequency, protons of water molecules within the body are forced out of equilibrium and spin along a designated Lamour frequency. When the strong magnetic field is switched off, the protons return to their natural state and the return time and released energy are captured and turned into a multitude of structural images, each only a few millimeters thick, visualizing the brain area of interest. Different tissues have various magnetic properties and can be distinguished in the structural images. 
MRI is particularly powerful when measuring gray matter changes and structural atrophy particularly in the hippocampus  ADDIN EN.CITE (Jack Jr et al., 2013; Taki et al., 2011). Functional MRI is considered a promising biomarker in AD because it is particularly sensitive to functional connectivity changes within the brain which are believed to precede structural changes leading to the possibility of earlier detection  ADDIN EN.CITE (Damoiseaux, 2012; Fayed, Dávila, Oliveros, Castillo, & Medrano, 2008). Computed tomography (CT) imaging has proven to be a useful alternative to MRI for individuals who have contraindications such as pacemakers but due to poor spatial resolution it is not ideal for evaluating Aβ or Tau pathology (Davis, Taveras, Roberson, & Ackerman, 1976). 
1.3.2	Positron Emission Tomography
Positron Emission Tomography (PET) is a nuclear functional imaging technique used to observe metabolic and molecular changes in vivo. Individuals are injected with a positron-emitting radiotracer which collides with electrons in the body producing gamma rays. The gamma rays are detected by a scanner producing 3D images of the brain. Radiotracers vary widely depending on the medical concern. Due to costs of operation and accessibility of radiotracers, PET is more commonly utilized in a research setting but has gained popularity in the clinical realm such as oncology and has shown promise in both cardiology and neurology (Anand, Singh, & Dash, 2009). 
Although AD is primarily diagnosed by the clinical manifestation of symptoms, PET and other neuroimaging modalities such as MRI provide an opportunity to identify changes within the brain and support the diagnosis. Two primary types of tracers have proven fruitful in AD research. The first, 18F-FDG, is an analog of glucose whose uptake concentrations can be indicative of resting state metabolic glucose activity within the brain. FDG-PET is useful in distinguishing not only between patients with AD and normal controls, but also among patients with different dementias types  ADDIN EN.CITE (Bloudek, Spackman, Blankenburg, & Sullivan, 2011; Mosconi, 2013). 
The second type, amyloid associated radiotracers, are used to identify Aβ deposition in the brain. In the past two decades, there has been a surge in promising tracers which correlate with Aβ in the brain. This development is increasingly important as a majority of evidence suggests the early role of amyloid in AD pathogenesis. Common tracers include 11C-Pittsburgh Compound-B, 18F-florbetapir, 18F-flutemetamol and 18F-florbetaben  ADDIN EN.CITE (Mathis et al., 2002; Rinne et al., 2012; C. C. Rowe et al., 2008; Wong et al., 2010) . Recent development of tau radiotracers has opened the field to explore tau and NFTs in-vivo. Detailed information regarding various radiotracers has been described elsewhere (Marcus et al., 2014).
1.3.2.1	Pittsburgh Compound-B
2-(4'-[11C]methylaminophenyl)-6-hydroxybenzothiazole, commonly referred to as Pittsburgh Compound-B (PiB), is an in vivo Aβ radiotracer designed to detect amyloid plaques in neuronal tissue. It is currently one of the most widely used Aβ tracers in research settings and has been shown to have significant retention in AD patients (Klunk et al., 2004). PiB has proven a useful tool in evaluating Aβ clearance therapies  ADDIN EN.CITE (Rinne et al., 2010). However, one major limitation of PiB is its relatively short half-life (20 minutes) requiring the use of an onsite cyclotron to produce the tracer before scans. A variety of 18F tracers with longer half-lives have been used commercially due to the restrictive operating costs, maintenance, and need for trained personnel  ADDIN EN.CITE (S. M. Landau et al., 2014). 
1.4	Personality
The American Psychological Association defines personality as the individual differences in characteristic patterns of thinking, feeling and behaving (American Psychological Association, 2018). Personality is considered an important factor in an individual’s overall mental health and can have both negative and positive impacts on an individual’s behavior and lifestyle. As personality change is a commonly recognized behavioral feature of AD diagnosis, it is important to understand how personality changes over the normal course of aging as well as in a diseased state. The following section provides a brief overview of personality before expanding on the currently dominant adult personality theoretical model: the five-factor model of personality	
1.4.1	Personality Over the Life Course
Two dominant viewpoints exist regarding stability of adult personality traits over time. The classic approach assumes that personality traits in an individual remain relatively static over the life course (McCrae et al., 2000). The opposing viewpoint, the radical contextual perspective, suggests personality is fluid and sensitive to life changes over time (Lewis, 2001). Existing research supports a blend of these two positions (Caspi, Roberts, & Shiner, 2005; Fraley & Roberts, 2005). Roberts and DelVecchio (2000) performed a meta-analysis which used rank-order consistency to evaluate change in personality over time. Rank-order consistency refers to an individual’s position in a particular trait relative to another or a population over time. The authors found that consistency between test-retest results increased over the life course from a correlation of 0.41 in early youth to 0.55 around age 30. Consistency began to plateau between the ages of 50 and 70 with a correlation of 0.70 leading them to hypothesize that personality traits change over the life course but only modestly in late life. 
One way to measure personality change is to examine mean level changes in the population. This method reflects generalizable patterns of personality change which apply to most people. One caveat is that it sacrifices individual variations of personality to gain a broader snapshot. Studies examining mean levels change have found aspects of extraversion, conscientiousness and emotional stability increase in early life reaching peak levels between ages 20-40. Measures of social vitality and openness are usually high in adolescence but have been noted to decrease with old age (Roberts, Walton, & Viechtbauer, 2006; Specht, Egloff, & Schmukle, 2011). Because many of these studies evaluate populations which are predominately white and highly educated, further research is needed to evaluate the validity of these findings among diverse populations and across cultures. 
1.4.2	The Five-Factor Model of Personality
In order for researchers to explore changes in personality across populations, it became increasingly important to develop a consistent way to examine personality. The five-factor model of personality is the prevailing model representing the higher-order structure of adult personality. The five-factor model consists of five basic personality domains often referred to as the “Big Five”: neuroticism, extroversion, openness, agreeableness, and conscientiousness. There has been little disagreement that neuroticism and extraversion are considered the “Big Two” personality traits in personality research. However, since the 1980s, growing support describing the remaining three factors as basic and pervasive cross-culturally has emerged (Costa Jr & McCrae, 1992). Though not exhaustive, the 5-factor model postulates that most facets of personality can be broadly categorized into these five domains. 
1.4.2.1	The NEOTM-FFI-3 Personality Assessment
Paul Costa, Ph.D. and Robert McCrae, Ph.D. are two American psychologists and who are well known for their development of the Neuroticism-Extraversion-Openness Personality Inventory (NEO-PI) which applies the five-factor model to assess individual personality. At its conception in the 1970s, the inventory only focused on three distinct domains and was called the Neuroticism-Extroversion-Openness Inventory (NEO-I) (P. T. Costa, Jr. & McCrae, 1976). After analysis of data emerging from the Baltimore Longitudinal Study of Aging (BLSA), Costa and McCrae determined the necessity of adding two additional domains to their inventory: Agreeableness and Conscientiousness (Paul T. Costa & Crae, 1978; Shock, 1984). 
By 1990, they produced the modified NEO-PI which was subsequently revised to the Revised NEO-Personality Inventory (NEO-PI-R) and is still in use today (P. T. Costa & McCrae, 1995; McCrae & Costa, 1987). Alternative changes in 2005 addressed the potential for the inventory to apply to a more generalized population including younger children and individuals with low literacy (McCrae, Costa, & Martin, 2005; McCrae, Martin, & Costa Jr, 2005). This inventory consists of 240 items and offers a shortened variant, the NEO-Five Factor Inventory-3 (NEO-FFI-3), consisting of a condensed 60 self-report items broken into 12 items for each of the five domains (McCrae & Costa Jr, 2007).The NEO-FFI-3 is particularly useful in a research setting when time is limited and the researcher wants to lessen the burden of surveys and questionnaires administered to the participant.
1.4.2.2	Neuroticism
Neuroticism is the tendency to express and experience negative emotions such as anger, worry, and frustration and is the most researched domain of the five-factor model due to its association with negative-affect and poorer mental health. Individuals who score low in neuroticism typically express greater emotional stability and are less reactive to stressors. Conversely, high neuroticism can manifest as a combination of inner-focused anxious distress such as anxiety and insecurity or outward-focused irritable distress in the form of hostility, jealousy and frustration. (Shiner & Caspi, 2003). Individuals high in neuroticism demonstrate increased negative emotion including higher perceived stress and low positive emotionality (Penley & Tomaka, 2002). Interestingly, multiple studies report an association between high neuroticism scores and blunted cortisol responses in the hypothalamic–pituitary–adrenal axis in response to acute stressors   ADDIN EN.CITE (Bibbey, Carroll, Roseboom, Phillips, & de Rooij, 2013; Oswald et al., 2006; Xin et al., 2017) 
	Neuroticism relates to a variety of common mental health disorders involving anxiety, mood and occasionally substance use (Ormel et al., 2013). Boyle et al. (2010) found that among primary care patients, neuroticism was associated with lower cognitive performance indicated by Mini Mental State Examination (MMSE) scores but the relationship was not moderated by depression severity. However, other studies indicate high neuroticism increases the risk of developing late life depression  ADDIN EN.CITE (Oldehinkel, Bouhuys, Brilman, & Ormel, 2001; Steunenberg, Beekman, Deeg, & Kerkhof, 2006). Neuroticism has been linked to a variety of brain regions associated with negative affect including increased functional connectivity in the anterior cingulate in response to negative facial expression and increased activation of the amygdala and insula during emotional processing tasks (Cremers et al., 2010; Stein, Simmons, Feinstein, & Paulus, 2007). Additionally, negative correlations have been demonstrated between neuroticism and striatum activation in individuals presented with rewarding stimuli (Schaefer, Knuth, & Rumpel, 2011). Interestingly, Wright et al. (2006) found higher neuroticism and extraversion showed significant negative correlations with cortical thickness in the frontal lobe.
Among a cohort of physically and cognitively healthy older adults studied over two decades, the highest quartile of neuroticism was associated with increased risk of developing dementia compared to lower quartiles (Terracciano et al., 2014). Additionally, informant reports have predicted dementia development two years post questionnaire assessment (Smith-Gamble et al., 2002). High levels of neuroticism may also moderate the relationship between SCCs and Aβ assessed using the memory functioning questionnaire (Snitz et al., 2015). Duchek, Balota, Storandt, and Larsen (2007) found that self and informant report of personality in individuals with MCI revealed an increase in neuroticism and decrease in conscientiousness relative to healthy controls. Of the five domains, neuroticism is the most consistently associated to AD  ADDIN EN.CITE (Balsis et al., 2005; Smith-Gamble et al., 2002; Terracciano, An, Sutin, Thambisetty, & Resnick, 2017; Terracciano et al., 2014).  
1.4.2.3	Extraversion
Extraversion, is the tendency to be talkative, sociable, and enjoy the company of others. Extraverts gain happiness from their external surroundings and have demonstrated a strong link to positive affect and sensitivity to reward  ADDIN EN.CITE (P. T. Costa, Jr. & McCrae, 1980; Smillie, DeYoung, & Hall, 2015). Neuroimaging studies show brain activity at rest or in response to positive stimuli are associated with extraverted personality as well as increased activation in dopaminergic and endogenous opioid systems  ADDIN EN.CITE (M. X. Cohen, Young, Baek, Kessler, & Ranganath, 2005; Depue & Morrone-Strupinsky, 2005; Wacker, 2018). While studying late life social activity and cognitive decline, James, Wilson, Barnes, and Bennett (2011) found that individuals with higher baseline extroversion scored higher on global cognition tests and that social activity was protective of cognitive decline over 5.2 years. Extraversion has been predictive of increased brain activation in dopamine associated areas including the anterior cingulate while lower extraversion scores have been linked to an increased risk of dementia development  ADDIN EN.CITE (Colin G DeYoung & Gray, 2009; Terracciano et al., 2014). The hippocampus, one of the first areas affected by AD associated atrophy, may be influenced by dopaminergic function  ADDIN EN.CITE (Fjell et al., 2014; McNamara & Dupret, 2017).  
1.4.2.4	Openness
Openness to experience, sometimes called intellect, reflects a tendency to appreciate new ideas, feelings, values, and behaviors. Open individuals are often intellectually curious and imaginative and open-minded. Although one of the least well studied and characterized domains of the five-factor model, openness has been associated with dorsolateral prefrontal cortex activation as well as a high result on a cognitive control test battery and working memory tasks  ADDIN EN.CITE (C. G. DeYoung, Peterson, & Higgins, 2005). When evaluating openness and risk of AD, Terracciano et al. (2014) found that only one facet of openness (openness to ideas) was associated with a 25% reduced risk of AD for each SD increased score. Others have found an association between higher openness and lower levels of Aβ and minor decreases in openness among individuals with mild AD symptomology (Duchek et al., 2007; Tautvydaitė, Antonietti, Henry, von Gunten, & Popp, 2017). In contrast, a meta-analysis of the five-factor model, conducted by Malouff, Thorsteinsson, and Schutte (2005) found no significant relationship between openness factors and symptoms of any common clinical disorders. 
1.4.2.5	Agreeableness
Agreeableness is the tendency to agree and go along with others rather than assert their own opinions. People scoring low on agreeableness are perceived  as competitive and argumentative while high scores suggest naiveite or submissiveness (Toegel & Barsoux, 2012). Agreeableness has been linked to emotional correlates including decreased anger proneness and reactive aggression and increased emotional control (Martin, Watson, & Wan, 2000). Agreeableness has also been related to greater volume of brain structures associated with social and emotional information processing including the superior temporal sulcus, temporoparietal junction and the posterior cingulate cortex  ADDIN EN.CITE (Cipriani, Borin, Del Debbio, & Di Fiorino, 2015; Saxe & Powell, 2006). The relationship between agreeableness and dementia is inconclusive with some suggesting high agreeableness confers a protective affect while other have found no relationship  ADDIN EN.CITE (Low, Harrison, & Lackersteen, 2013; Terracciano et al., 2014). When comparing healthy middle and old age controls with participants ranging from very mild to mild AD, Duchek et al. (2007) found no mean levels differences in agreeableness between the groups. 
1.4.2.6	Conscientiousness
Conscientious individuals tend to be careful, follow rules, and desire to do tasks well. They take obligations seriously and have a strong drive to achieve. Conscientiousness represents the ability to focus on long term goals while refraining from impulse urges. Conscientiousness was found to co-vary with regions involved with planning and voluntary control and behavior including the lateral prefrontal cortex (Colin G. DeYoung et al., 2010). It has been hypothesized that low levels of blood glucose may be involved with impaired self-control, a trait highly correlated with conscientiousness (Gailliot et al., 2007). Among individuals with type 1 diabetes, individuals with high agreeableness and conscientiousness had lower and more stable HbA1c over a 3-year study period (Waller et al., 2013). While conscientiousness typically increases over the life course, late-life decreases have been associated with MCI and dementia outcomes (Balsis et al., 2005). Susan M. Landau et al. (2011) examined FDG-PET regions of interest including the right and left angular gyri, bilateral posterior cingulate gyrus, left and right middle/inferior temporal gyri and found that all 5 regions exhibited decreased glucose metabolism compared to individuals with MCI and healthy controls. The rate of metabolic decline was greatest among AD participants over a 2-year study period. When comparing the quartiles of conscientiousness scores, Terracciano et al. (2014) found that 10% of the study population AD cases could be attributed to the lowest quartile conscientiousness score. 
1.5	A summary of Alzheimer’s Disease, Amyloid-B, and Personality 
AD pathology including Aβ plaques and NFTs are believed to accumulate as much as a decade or more before the clinical onset of AD. Research has established a strong correlation between the presence of Aβ in the brain and AD  ADDIN EN.CITE (Selkoe & Hardy, 2016). Evidence suggests that Aβ burden in older adults is predictive of an increased risk of AD development over time (Pike et al., 2007). The discovery of novel Aβ biomarkers and the use of neuroimaging technologies have opened the doors for researchers to better understand not only how Aβ functions in a diagnosed disease state, but also how Aβ accumulation in a healthy at-risk population differs from disease.
Although it is well established that personality and behavior changes are common clinical features of AD, less is known about the role of personality change before the clinical onset of disease. Previous literature has demonstrated that high neuroticism and low levels of extraversion and conscientiousness are related to AD outcomes while there is less definitive evidence regarding the role of openness and agreeableness in AD development. Additionally, there is currently no conclusive research which demonstrates whether personality change precedes clinical diagnosis of dementia  ADDIN EN.CITE (Duberstein et al., 2011; Ringman et al., 2015; C. C. Rowe et al., 2008; Tautvydaitė et al., 2017; Terracciano et al., 2017; Yoneda, Rush, Berg, Johansson, & Piccinin, 2017). 
Two views have emerged to explain the relationship between personality and AD: The Reverse Causality hypothesis and the Risk factor hypothesis. The Reverse Causality hypothesis posits that personality change reflects behavioral change and acts as an early indicator of subclinical AD neuropathology. Personality is often associated with the progression of AD and a clinical diagnosis of dementia requires indicators of personality and behavioral change (Cipriani et al., 2015; Duchek et al., 2007). The Risk factor hypothesis examined by  ADDIN EN.CITE Terracciano et al. (2017) posits that personality is a true risk factor for AD and precedes any AD associated pathology. If this is the case, longitudinal assessment of personality change in non-demented individuals may not be as informative in predicting AD. Rather, single personality assessments including the NEO-FFI-3 may be used to identify those at the highest risk for AD development  ADDIN EN.CITE (Duberstein et al., 2011; Johansson et al., 2014; Terracciano et al., 2017) 
1.5.1	Gap in the Literature
Though Aβ and personality have been strongly linked to the development of AD, very little research exists examining the relationship between the two. Snitz et al. (2015) found that the highest levels of neuroticism may moderate the relationship between subjective cognitive complaints and Aβ in clinically normal adults but did not specifically address the role of personality on Aβ levels. Previous literature indicates that both factors may play a role in the preclinical development of AD yet their relationship remains unknown. The two studies within this paper aim to explore the relationship between personality change and Aβ particularly among non-demented older adults. 
1.6	Public Health Significance 
The health burdens of older adults are a major public health concern. Not only does this population have a high prevalence of chronic disease, but many suffer from multiple conditions representing a significant mental, physical and financial burden on the individual as well as the healthcare system. Since 2000, heart disease deaths, another major chronic disease concern in the United States, decreased by 14% while AD associated deaths increased by 89% (Alzheimer's Association, 2017a). In 2017, an estimated $175-259 billion was spent caring for someone with AD or another dementia. The average annual per person Medicare spending for a senior with AD or other dementias averaged $23,497 compared to $7,223 for a senior without dementia (Alzheimer's Association, 2017b). 
According to clinicaltrials.gov over 400 AD studies are actively recruiting participants to be involved in research. However, no new drug for AD has been approved by the FDA in over a decade resulting in millions of dollars lost on drug trials. This may be one major indicator that interventions are attempting to intervene too late in the pathologic process. Research investigating risk factors and early predictors of AD including personality change and Aβ can help provide powerful insights to novel treatment targets as well as inform patient care. 
2.0 	Objectives
The objective of this research was twofold. Analysis 1 aimed to examine the cross-sectional association between baseline Aβ levels using PiB status (+/-) and personality scores in cognitively normal adults. We hypothesize that neuroticism and conscientiousness will be associated with PiB status. Analysis 2 aimed to evaluate the Reverse Causality Hypothesis by testing whether Aβ levels at baseline predict change in personality in non-demented older adults over time. In support of evidence against the Reverse Causality hypothesis, we hypothesize there will be no relationship between baseline Aβ levels and personality change over time. 
3.0 	Methods
Data was collected between 2010 and 2017 from two separate ongoing University of Pittsburgh imaging cohort studies. Parent Study 1 focused on normal aging and Aβ (Nebes et al., 2013) while Parent Study 2 explored normal aging, Aβ, and vascular interaction in the oldest old (A. D. Cohen et al., 2009). 
3.1	Assessment of Amyloid-β
As part of the routine study visits, a subsample of individuals from both parent studies completed repeated PiB-PET scans every 12-24 months. During this visit, all participants were fitted with an intravenous catheter in an antecubital vein for a 20-second PiB radiotracer injection and subsequent 90-minute PiB-PET scan. Detailed description of PET data collection and analysis has been previously described elsewhere  ADDIN EN.CITE (Price et al., 2005). 
Radioactivity concentration in six regional brain tissues (anterior cingulate, anterior-ventral striatum, frontal cortex, lateral temporal cortex, parietal cortex, and precuneus cortex) was normalized to injected PiB dosage and body mass values to create a standard uptake value (SUV) for each region. Each SUV was then divided by its precise regional reference SUV representative of nonspecific radiotracer retention to generate a standard uptake value ratio (SUVR). All six SUVRs were then averaged to generate a global PiB SUVR representing a true Aβ-tissue ratio. (Nebes et al., 2013). For this research, individuals were further categorized as PiB(+) if they exceeded a predetermined 1.57 global PiB SUVR cut point (A. D. Cohen et al., 2013). Individuals with <1.57 global PiB SUVR were categorized as PiB(-). 
3.2	Personality Traits Assessment
At the time of each PiB-PET scan, a subsample of individuals completed a paper version self-report (Form S) NEOTM-FFI-3 personality assessment. Items were answered on a 5-point Likert scale: 1. Strongly Disagree, 2. Disagree, 3. Neutral, 4. Agree, 5. Strongly Agree. Individuals who recorded a total of 4 or more missing NEO scores or 2 or more missing scores in a single domain were considered invalid. For valid tests with missing data, each missing item value was replaced with the median “neutral” value. Item values for each of the 5 personality domains were summed in accordance with the NEO NEOTM-FFI-3 to create domain specific scores for each individual. 
3.3	Participant Selection Criteria
The participant selection schema for analyses 1 and 2 can be found in Figure 2. Exclusion criteria in parent study 1 was stricter than most cognitive aging studies due to their attempt to include only those who were “clinically unimpaired”. Exclusion criteria included a history of psychiatric or central nervous system disease, use of psychoactive medications, a score of >15 on the Geriatric Depression Scale (Yesavage et al., 1982), contraindications for receiving a MRI, and neuropsychological test battery result suggesting the presence of dementia or mild cognitive impairment (Nebes et al., 2013).  Parent study 2 examined both controls and individuals with MCI or AD.  Participants received a full neuropsychological evaluation including review of medical history and physical evaluation. AD, MCI and cognitively normal status were adjudicated by diagnostic consensus conference (Snitz et al., 2013). Additionally, amyloid positivity status was confirmed as previously described by Aizenstein et al. (2008).




Figure 2. Participant Selection Schematic

3.3.1	Analysis 1
A total of 173 Individuals completed one or more NEOTM-FFI-3 assessments. Of these individuals, 58 were classified as having mild cognitive impairment or dementia at baseline and removed. 2 additional individuals had missing cognitive data. From 113 remaining cognitively normal adults, an additional 7 were removed due to missing Aβ data. The final sample of 106 individuals were included in Analysis 1. 
3.3.2	Analysis 2
From the final sample of 106 cognitively normal individuals at baseline in analysis 1, individuals from parent study 2 were removed (n=44) because they were outliers on age as well as lacked follow-up data. After exclusion criteria were applied, 62 individuals with baseline data were included in analysis 2. Of the 62 individuals, 40 completed a second follow-up assessment and 15 completed a total of 3 assessments. 
3.4	Statistical AnaLYSIS OF aMYLOID-b AND pERSONALITY
All variables were tested for normality using Q-Q plots and the Kolmogorov-Smirnov test. To test the cross-sectional relationship between Aβ and personality (Analysis 1), an Independent Samples T-Test was used to evaluate group level means of each 5-factor personality domain scores between PiB status groups (+/-). Additionally, One-way Analysis of Covariance (ANCOVA) controlling for baseline age and MMSE scores was conducted using first the total group and second stratified by APOE status. Sex was not associated with PiB status or the 5-factor personality domain scores and thus not controlled for in the analyses. To test the longitudinal relationship between baseline Aβ and personality (Analysis 2), five marginal mixed effect models with compound symmetric g-matrices were used. The outcomes of interest were each of the 5 personality factor domain scores over a maximum of 5.25 years of follow-up with approximately 2-year intervals between visits. All linear mixed models controlled for baseline age and follow-up time from baseline in years.  
4.0 	rESULTS
4.1	Analysis 1
A total of 106 PiB(-) (n=60) and PiB(+) (n=46) individuals were included in this analysis. The mean age of PiB(-) individuals was 78.9(8.5) with a range of 65-93 and the mean age of PiB(+) individuals was 83.5(6.7) with a range of 66-98. For both groups, education averaged 15.3 years. Individuals in the PiB(-) group were more likely to be female (58%) compared to the PiB(+) group (41.3%). A vast majority of both groups were self-identified Caucasian 85.0% and 95.7% respectively. 21 individuals had at least one APOE4 allele and 8 individuals were missing APOE4 information including 7 from the PiB(-) group and 1 from the PiB(+) group. PiB(-) group scored on average higher on the MMSE (Table 1). 

Table 1. Analysis 1: Baseline Demographics


Five-factor personality domain scores at baseline can be found in table 2. An independent samples t-test was conducted to compare mean personality domain scores between PiB status groups. Before adjustment, there was a significant difference in neuroticism scores between PiB(-) (M=13.3, SD=6.1) and PiB(+) (M =15.5, SD =4.8); t(104) =-2.032, p = .045. There was also a significant difference in conscientiousness scores for PiB(-) (M=29.5, SD=5.4) and PiB(+) (M =27.3, SD =5.2); t(104) = 1.999, p =.048. No other domains were significant. 
Associations for neither neuroticism nor conscientiousness remained significant after adjustment for baseline age and MMSE score in an ANCOVA model. However, of the five domains, baseline neuroticism remained the most closely associated with PiB status. Baseline age was significantly associated with openness score F(1,103) =4.856,  p=.030, ηp2 =0.024, and conscientiousness score F(1,103) =7.075, p =.009, ηp2 =0.014, after controlling for PiB status and MMSE score.

Table 2. Analysis 1: Baseline Five-Factor Personality Domain Scores


To address the possibility of APOE carrier status moderating the relationship between PiB status and the five-factor personality domain scores, an additional ANCOVA model stratified by APOE4 Status was conducted (table 3). Among individuals with at least one APOE allele variant, PiB(+) status was significantly associated with higher neuroticism score F(3,17)= 4.918, p= .040, ηp2= 0.224 and lower conscientiousness score, F(3,17)=13.665, p=.002, ηp2=0.260 and MMSE score  F(3,17)=5.282,  p=.035, ηp2=0.195. 
Table 3. Analysis 1: Five-Factor Personality Domain Scores at Baseline by APOE4 Status 

Model Adjusted for baseline age and MMSE score
4.2	Analysis 2
A total of 62 individuals were included in this analysis. Of the 62, 64.5% (n=40) completed a second assessment and 24.2% (n=15) completed a total of three assessments. The variables of interest were collected over a maximum of 5.25 years of follow-up with approximately 2-year intervals between assessments. In total, individuals completed between 1 and 3 assessments. Baseline demographic information can be found in table 4. The mean baseline age was 75(6.4) with a range of 65-93. Mean education was 14.8(2.4) years. The sample was predominately female (64.5%) and Caucasian (83.9%). At least one APOE4 allele was present in 22.6% (14/57). The average PiB SUVR value was 1.59(0.34) and the mean MMSE score was 28.9(1.3).




Mean change between assessments from the NEO-FFI-3 personality can be found in table 5. Mean neuroticism initially declined 0.19 points then raised 0.22 points between assessment 2 and 3. There was a total positive mean change of 0.03 points. Mean extraversion increased 0.45 points between baseline and assessment 2 before declining 1.5 points after the second assessment resulting in a net change of -1.5 points over three assessment periods. Mean openness increased by 0.45 points from baseline to assessment 2 then decreased -1.97 points resulting in a net change of -1.5 points. Mean agreeableness score increase between baseline and assessment 1 by 0.18 points and an additional 0.7 points between assessments 2 and 3 resulting in a net change of 0.88 points. Mean conscientiousness score initially declined 0.18 points between baseline and assessment1 and increased 0.52 points between assessments 2 and 3 resulting in a net change of 0.34 points. It is important to note that due to the smaller sample sizes during follow-up assessments, change scores reflect the change of only a subsample of the study population at baseline and may not be representative of the total change in the sample population. 
Table 5. Analysis 2: Mean Five-Factor Personality Domain Change Between Assessments


In the univariate longitudinal model examining change in neuroticism, baseline global PiB SUVR was significantly associated with change in neuroticism score (β=0.4365, p=.040). Although this relationship did not survive adjustment for baseline age and follow-up at a level of p<.05, global 6 PiB β coefficients indicate a 3.27 times greater effect on neuroticism score when compared to baseline age (β=0.396, p=.059). Baseline age was significantly associated with negative change in openness and conscientiousness. Each one-year greater baseline age was associated with a -0.271 decrease in openness score (p=.010) and a -0.225 decrease in conscientiousness score (p=.031) after accounting for baseline global PiB SUVR and follow-up in years). In all adjusted longitudinal models, there was no association between follow-up time and change in personality score (Table 6). 
















This research examined personality change and Aβ before the onset of any clinical symptomology of AD. The present results indicate a relationship between baseline Aβ and both neuroticism and conscientiousness scores as well as suggest a tentative relationship between baseline global PiB SUVR and change in neuroticism over time in cognitively normal older adults and warrants further exploration in future studies.
Analysis 1 indicated that neuroticism and conscientiousness are most closely related with PiB status at baseline consistent with the proposed hypothesis. Although, this relationship did not survive adjustment for age and MMSE score, it is consistent with finding by Terracciano et al. (2014) who found that highest levels of neuroticism and lowest quartiles of conscientiousness were associated with increased risk of AD development. The presence of APOE4 variants have been linked with abnormal clearance of Aβ resulting in higher levels of brain Aβ (Castellano et al., 2011). To better understand the potential impact of APOE on personality and Aβ, Analysis 1 was rerun after stratification by APOE4 status. Higher Aβ indicated by PiB(+) status was significantly associated with higher mean neuroticism score (p=.040) and lower mean conscientiousness score (p=.002) among those with at least one APOE4 allele. Similar results have been found in previous studies where decreased cognitive function and incident AD were most common among individuals with high neuroticism and extroversion as well as APOE4 allele(s)  ADDIN EN.CITE (Dar-Nimrod et al., 2012). These results indicate that high levels of neuroticism may be related to Aβ levels particularly among those with at least one APOE4 allele. This research also highlights the importance of genotype-phenotype interactions when evaluating the relationship between Aβ, personality and AD. 
The second analysis examined the longitudinal relationship between baseline Aβ and personality change. To better account for a range of PiB values, analysis 2 used global PiB SUVR rather than PiB status. Both structure and function of Global PiB SUVR Regions of interest including the anterior cingulate, anterior ventral striatum and frontal lobes have been linked to neuroticism and extraversion  ADDIN EN.CITE (Cremers et al., 2010; Schaefer et al., 2011; Wright et al., 2006). In this analysis, Aβ was significantly associated with neuroticism change in the univariate model but did not survive adjustment for baseline age and follow-up. However, baseline global PiB SUVR demonstrated a 3.27 times greater effect on neuroticism score when compared to baseline age. There was no significant relationship between baseline global PiB SUVR and extraversion. Only openness (β =-0.271, p=0.010) and conscientiousness (β = -0.225, p=0.031) were associated with baseline age and there was no association between length of follow and personality change. 
 ADDIN EN.CITE Terracciano et al. (2017) similarly explored change in personality to address the question whether increased neuroticism, decreased conscientiousness and overall change in personality preceded mild cognitive impairment. Consistent with the results of the analysis included within this paper, Terracciano et al. (2017) found that individuals higher in neuroticism and lower in conscientiousness were more likely to develop dementia over a mean 12 years of follow up. The authors found no significant association between change in personality and development of dementia before clinical onset. Taken together these results do not support evidence of the reverse causality hypothesis but indicate that high neuroticism and low conscientiousness may be important risk factors predicting the clinical development of AD particularly among individuals with at least one APOE4 allele. 
Strengths of this study include use of participant information gathered from existing well-defined cohorts of two brain imaging studies at the University of Pittsburgh. Many participants from these cohorts participated in multiple assessments providing longitudinal data for both PiB-PET and personality assessments. Because both assessments are conducted concurrently the data have a strong temporal relationship. The inclusion of both cross-sectional and longitudinal data allows us to examine baseline relationships as well as the temporal relationship between PiB and personality domain scores. The inclusion of APOE status allows for consideration of important genetic factors associated with increased risk of AD. Finally, this is the first study to our knowledge to examine the relationship between an in-vivo Aβ marker and self-reported personality in non-demented older adults. 
The primary limitation of this research is limited follow-up data resulting in follow-up time ranging from 1.58 to 5.25 years with a maximum of 2 additional visits post baseline reduced our power to detect significant change over time if one truly exists. Only 64.5% of the initial analysis 2 cohort had data from a second assessment and only 24.5% has data at three-time points. Although linear mixed models are robust to missing data, lack of follow-up data within this study limits interpretation. Previous research has indicated that personality in non-demented adults may change over longer periods of time and may not be captured in this short timeframe  ADDIN EN.CITE (Duberstein et al., 2011; Johansson et al., 2014; Roberts et al., 2006). Additional limitations include the inability to examine the relationship between depression/ depressive symptoms and dementia due to lack of information regarding depressive state as the time of assessment. High neuroticism has been shown as a predictor of depression onset in later life  ADDIN EN.CITE (Steunenberg et al., 2006) and depression diagnosis may confer increased risk for decline in cognitive function particularly among individuals with high neuroticism (Boyle et al., 2010). It is important that future studies consider this relationship in similar studies. This research is considered preliminary and data on PiB-PET and personality measures continue to be collected as part of the routine assessment in both parent studies. Additional data added to this analysis will help to provide more robust estimates regarding the association between personality change and Aβ markers related to AD. 
An alternative way to address the issue of limited follow-up is to consider another statistical method for data analysis. In this case, it is possible to use a linear regression model evaluating baseline Aβ and personality domain change scores of the five personality domains. The change score is reflective of the mean level change and reflects the average change between the two groups (Hedeker & Gibbons, 2006). While this method may help to reduce challenges associated with missing data it has two primary drawbacks. First, a change score must be calculated from the first and last data available for each individual. This results in the loss of information for additional existing timepoints by simplifying the data to baseline and end measures. Second, mean level analysis reduces the amount of information gained on the individual level in favor of understanding the broader pattern (Roberts et al., 2006) . 
In conclusion, analysis 1 found a significant association between both higher mean neuroticism and lower mean conscientiousness with PiB(+) status among individuals with at least one APOE4 allele. Analysis 2 found no significant longitudinal association between Aβ and personality in non-demented older adults. However, there was a trend toward an association between baseline Aβ and change in neuroticism. Decreased openness and agreeableness were associated with increased age even after controlling for follow-up time and global PiB SUVR. This research provides preliminary evidence regarding the association between two important factors: Aβ and personality in AD as well as their relationship with the APOE gene. Furthermore, these findings are inconsistent with the Reverse Causality hypothesis of personality in AD progression and have important public health significance as they add to better understanding of brain and personality changes in older adults at risk of developing AD.  
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Table 6. Linear Mixed Effects Models of 5-Factor Model Domains as a Function of Global 6 PiB SUVR, Age, and Follow Up (Years)
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